The Eurofins Network Expands Its BioPharma Product Testing Offering in the United States With the Acquisition of Infinity Laboratories, Inc.
2024年9月16日 - 2:15PM
ビジネスワイヤ（英語）
Regulatory News:
Eurofins (Paris:ERF):
Eurofins Scientific (EUFI.PA), a global leader in BioPharma
Product Testing, announces the closing of its acquisition of
Infinity Laboratories, Inc. (“Infinity”). Founded in 1991, Infinity
operates eight state-of-the-art laboratories across the United
States and employs approximately 100 staff. Infinity’s significant
microbiology testing footprint with best-in-class systems provides
local services in key regions of the country, expanding the
Eurofins microbiology footprint. The company also offers chemistry,
sterilisation, and package testing to pharmaceutical, biotechnology
and medical device clients. Its package testing services in
California provide an ideal complement to Eurofins’
Pennsylvania-based package testing services. Infinity’s core
competencies, client relationships, and geographic coverage also
complement and enhance the Eurofins network’s extensive portfolio
in BioPharma Product Testing and Medical Device Testing services to
clients across the United States and around the world.
The acquisition further bolsters the Eurofins BioPharma and
Medical Device Testing network’s national and global footprint to
provide the most comprehensive and competitive service offering in
the industry. In return, Infinity and its clients gain access to
Eurofins' extensive laboratory network, analytical portfolio and
leading IT systems.
Comment from Dr Gilles Martin, Eurofins CEO: "We are very
pleased to welcome Infinity’s teams to Eurofins. The addition of
Infinity’s laboratories and competencies to Eurofins’ leading
BioPharma Services network of companies further increases our
leadership in providing the most innovative, high-quality and
cost-competitive services and IT systems to our clients.”
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. The Eurofins Scientific S.E.
network of independent companies believes that it is a global
leader in food, environment, pharmaceutical and cosmetic product
testing and in discovery pharmacology, forensics, advanced material
sciences and agroscience contract research services. It is also one
of the market leaders in certain testing and laboratory services
for genomics, and in the support of clinical studies, as well as in
biopharma contract development and manufacturing. It also has a
rapidly developing presence in highly specialised and molecular
clinical diagnostic testing and in-vitro diagnostic products.
With ca. 62,000 staff across a decentralised and entrepreneurial
network of more than 900 laboratories in over 1,000 companies in 62
countries, Eurofins offers a portfolio of over 200,000 analytical
methods to evaluate the safety, identity, composition,
authenticity, origin, traceability and purity of a wide range of
products, as well as providing innovative clinical diagnostic
testing services and in-vitro diagnostic products.
Eurofins companies’ broad range of services are important for
the health and safety of people and our planet. The ongoing
investment to become fully digital and maintain the best network of
state-of-the-art laboratories and equipment supports our objective
to provide our customers with high-quality services, innovative
solutions and accurate results in the best possible turnaround time
(TAT). Eurofins companies are well positioned to support clients’
increasingly stringent quality and safety standards and the
increasing demands of regulatory authorities as well as the
evolving requirements of healthcare practitioners around the
world.
The Eurofins network has grown very strongly since its inception
and its strategy is to continue expanding its technology portfolio
and its geographic reach. Through R&D and acquisitions, its
companies draw on the latest developments in the field of
biotechnology and analytical chemistry to offer their clients
unique analytical solutions.
Shares in Eurofins Scientific S.E. are listed on the Euronext
Paris Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg
ERF FP).
About Infinity
Infinity Laboratories was founded in 1991 as a regional
microbiology laboratory committed to quality solutions and customer
success. Today, Infinity has expanded into eight facilities across
the United States to proudly serve its pharmaceutical,
biotechnology and medical device partners with the combined
flexibility and customer engagement of a local partner and the
best-in-class systems of a coast-to-coast network.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240915133411/en/
Notes to Editors:
For more information, please visit
www.eurofins.com or contact:
Investor Relations Eurofins Scientific SE Phone: +32 2 766 1620
E-mail: ir@sc.eurofinseu.com
Enerplus (NYSE:ERF)
過去 株価チャート
から 12 2024 まで 1 2025
Enerplus (NYSE:ERF)
過去 株価チャート
から 1 2024 まで 1 2025
